To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

A Proof of Concept, Non-randomized, One Center Study to Explore the Safety and Efficacy of 16 Weeks of Treatment With Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

Treatment Trials

Focus your search

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

Description

Conditions